Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tilray Brands Inc TLRY

Alternate Symbol(s):  T.TLRY

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.


NDAQ:TLRY - Post by User

Post by quinlashon Mar 25, 2024 8:04pm
146 Views
Post# 35951929

HHS Recommends Cannabis (Article Clips + Letter to DEA)

HHS Recommends Cannabis (Article Clips + Letter to DEA)Not too sure how many folks actually took the time to research the HHS Letter of Recommendation to Reschedule Cannabis however, due to mis-statements made on this forum today I am opting to put out the facts in case there are a few out there trading in potentially the wrong direction.

Below are CLIPS from the article I link to at the bottom of the post.  For the full article use the link to see it all.

Do some folks a favor, if you are on mutiple forums then copy and paste this post and share it or simply share a link - Cannabis Bulls thank you.


(Article) HHS Releases Unredacted Report Recommending Cannabis Rescheduling

"On August 29, 2023, the U.S. Department of Health and Human Services (HHS) submitted an analysis to the Drug Enforcement Agency (DEA) recommending that cannabis be rescheduled as a Schedule III controlled substance. HHS finally made this report public in its unredacted form last Friday"

"... enough data for HHS to conclude, in the totality, that medicinal use of cannabis has scientific support. HHS also considered the use of cannabis in the treatment of anxiety, epilepsy, PTSD, and inflammatory bowel disease ... "


Link to full Article
https://www.shipmangoodwin.com/insights/hhs-releases-unredacted-report-recommending-cannabis-rescheduling.html


Clip from HHS Letter of Recommendation to Reschedule To Schedule III (Page 25)

In Part 1 of the CAMU test, OASH identified at least 15 medical conditions where there is widespread current experience with medical use of the substance in the United States by licensed HCPs operating in accordance with implemented state authorized programs, where the medical use is recognized by entities that regulate the practice of medicine.
 
These conditions include amyotrophic lateral sclerosis (ALS), autism, cachexia, cancer, chronic pain, Crohn’s disease, epilepsy or condition causing seizures, glaucoma, HIV/AIDs, multiple sclerosis, Parkinson’s disease, persistent/severe muscle spasm, persistent/severe nausea, PTSD, and spasticity. FDA conducted Part 2 of the analysis for the medical conditions identified by OASH that were likely to have the most robust evidence available for review; because the analysis concluded that the Part 2 test has been met for at least one of the conditions identified in Part 1, there was no need to analyze all of them

Link to:
BASIS FOR THE RECOMMENDATION TO RESCHEDULE MARIJUANA IN TO SCHEDULE III
OF THE CONTROLLED SUBSTANCES ACT


https://www.dropbox.com/scl/fi/pw3rfs9gm6lg80ij9tja6/2023-01171-Supplemental-Release-1.pdf?rlkey=v5atj0tcnhxhnszyyzcwdcvvt&dl=0




<< Previous
Bullboard Posts
Next >>